An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases | MicrobiomeTrials← Back to trialsNCT05732402
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-03-15Est. Completion: 2028-03-02
Enrollment target: 72 participants Locations- Investigational Site (523), Phoenix, Arizona, United States
- Investigational Site (501), Phoenix, Arizona, United States
- Investigational Site (524), Tucson, Arizona, United States
- Investigational Site (506), Valencia, California, United States
- Investigational Site (513), Arvada, Colorado, United States
- Investigational Site (512), Orlando, Florida, United States
- Investigational Site (525), Tamarac, Florida, United States
- Investigational Site (502), Lawrenceville, Georgia, United States
- The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Investigational Site (503), Boston, Massachusetts, United States
- Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
- Investigational Site (509), Newark, New Jersey, United States
- Investigational Site (511), Albany, New York, United States
- Investigational Site (508), Brooklyn, New York, United States
- Investigational Site (518), Bethlehem, Pennsylvania, United States
- Investigational Site (118), Colleyville, Texas, United States
Other microbiome trials you might be interested in
Systemic Lupus Erythematosus (Sle)Primary Ovarian Insufficiency (Poi)
Background:
Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. Peop…
Bethesda, United StatesEst. completion May 31, 2027
SLE (Systemic Lupus)Lupus Erythematosus, SystemicLupus NephritisSystemic SclerosisInflammatory Myopathy, IdiopathicMyositisDiffuse Cutaneous Systemic Sclerosis
Investigational Site (516), Houston, Texas, United StatesInvestigational Site (526), Irving, Texas, United StatesInvestigational Site (519), Concord, New South Wales, AustraliaInvestigational Site (515), Saint Albans, Victoria, AustraliaInvestigational Site (102), Nedlands, Western Australia, AustraliaInvestigational Site (191), Caguas, Puerto RicoInvestigational Site (507), Cheonan, Chungcheongnam-do, South KoreaInvestigational Site (505), Anyang-si, Gyeonggi-do, South KoreaInvestigational Site (504), Goyang-si, Gyeonggi-do, South KoreaInvestigational Site (510), Guri-si, Gyeonggi-do, South KoreaInvestigational Site (125), Seoul, Gyeonggi-do, South KoreaInvestigational Site (520), Seoul, Gyeonggi-do, South KoreaInvestigational Site (521), Seoul, Gyeonggi-do, South KoreaInvestigational Site (116), Suwon, Gyeonggi-do, South KoreaThis is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary effica…
La Jolla, United StatesEst. completion Dec 31, 2031
Systemic Lupus Erythematosus
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how…
Bethesda, United States